Clinical trials: Processes, Metabolic
Gout and Hyperuricemia
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in…
- Trial name
- NCT02078219
- Testing
- RDEA3170, Allopurinol
- Where
- 14 sites in Japan
- Volunteers
- 204 people
- Sponsor
- AstraZeneca
Chronic Kidney Diseases, Bone Loss
Bone in CKD Alkali Response (BICARb Pilot Trial)
The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease.
- Trial name
- BICARb (NCT05918029)
- Testing
- Potassium Citrate Extended Release Oral Tablet, Potassium Citrate and Citric Acid Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Albert Einstein College of Medicine
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Coronary Artery Bypass Surgery, Postoperative Complications
Glutamate for Metabolic Intervention in Coronary Surgery II
The aim of GLUTAMICS II is to evaluate whether intravenous glutamate infusion surgery reduces the risk of postoperative heart failure as measured by plasma NT-proBNP in patients undergoing moderate to high-risk coronary artery…
- Conditions
- Coronary Artery Bypass Surgery, Postoperative Complications, Heart Failure
- Trial name
- GLUTAMICSII (NCT02592824)
- Testing
- glutamate infusion, saline infusion
- Where
- 4 sites in Sweden
- Volunteers
- 321 people
- Sponsor
- University Hospital, Linkoeping
Chronic Kidney Diseases, Hypertension
Chronic Kidney Disease Clinical Decision Support
To prevent serious chronic kidney disease (CKD) complications such as end-stage renal disease and cardiovascular events, better strategies are needed to identify, treat, and refer CKD patients seen in primary care clinics.
- Conditions
- Chronic Kidney Diseases, Hypertension, Diabetes
- Trial name
- CKD-CDS (NCT03890588)
- Testing
- CKD enhanced clinical decision support
- Where
- United States
- Volunteers
- 6,295 people
- Sponsor
- HealthPartners Institute
Cirrhosis
A Trial to Improve Quality of Life in People With Cirrhosis
This trial is being completed to evaluate whether a crystallized form of lactulose (Kristalose) will improve quality of life, sleep and cognitive function in patients with cirrhosis that have not been diagnosed with Hepatic…
- Trial name
- NCT05061992
- Testing
- Lactulose
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Michigan
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Metabolic Syndrome
Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program
Since 2009, a programmatic community-based strategy (COPE) has been implemented to address health disparities among Navajo individuals living with multiple chronic conditions.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome, Hypertension, Chronic Disease
- Trial name
- NCT03326206
- Where
- 6 sites in United States
- Volunteers
- 28,813 people
- Sponsor
- Brigham and Women's Hospital
Endothelial Function, Lipids
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
The purpose of this study is to determine the safety and effects of etravirine, an HIV antiretroviral medication, on vascular function.
- Conditions
- Endothelial Function, Lipids, Insulin Resistance, Inflammation
- Trial name
- NCT00871234
- Testing
- Etravirine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Indiana University
Metabolic Syndrome, Insulin Resistance
Effects of Fish Oils on Inflammation and Insulin Resistance
The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic…
- Trial name
- NCT00579436
- Testing
- omega-3 fatty acid
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Philip Kern
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to…
- Trial name
- CONFIDENCE (NCT05254002)
- Testing
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Finerenone (BAY94-8862 ) 20 mg
- Where
- 173 sites in United States, Belgium and 12 more
- Volunteers
- 1,664 people
- Sponsor
- Bayer
Dehydration
Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)
The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase…
- Trial name
- INFUSE-AT1A (NCT01116102)
- Testing
- Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Baxter Healthcare Corporation
Thromboembolism
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
The purpose of this study is to determine whether DNA analysis improves the efficiency of dosing and safety in patients who are being started on warfarin therapy.Warfarin, a blood thinner (anticoagulant) prescribed to 1-2 million…
- Trial name
- Coumagen-II (NCT00927862)
- Testing
- IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
- Where
- United States
- Volunteers
- 2,415 people
- Sponsor
- Intermountain Health Care, Inc.
Infant Mortality, Preterm Birth
Antenatal Micronutrient Supplementation and Infant Survival
The purpose of this community-based randomized trial is to examine whether a daily antenatal and postnatal multiple micronutrient supplement given to women will enhance newborn and infant survival and health and other birth…
- Conditions
- Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality
- Trial name
- JiVitA-3 (NCT00860470)
- Testing
- Iron (27 mg) - folic acid (600 ug), Multiple micronutrient
- Where
- 2 sites in United States, Bangladesh
- Volunteers
- 44,567 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Non Communicable Diseases, HIV
Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia
This mixed-methods formative research study aims to adapt the WHO Package of Essential Noncommunicable Disease Interventions (WHO-PEN) approach for the Zambian public health system, and pilot test an adapted, streamlined, and…
- Trial name
- TASKPEN (NCT05005130)
- Testing
- TASKPEN
- Where
- 4 sites in Zambia
- Volunteers
- 1,129 people
- Sponsor
- University of North Carolina, Chapel Hill
Hyperkalemia, End Stage Renal Disease
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
The purpose of this study is to determine whether once-daily dosing of patiromer will reduce the frequency of hyperkalemic episodes in ESRD (end stage renal disease) study participants who receive conventional hemodialysis (HD).
- Trial name
- NCT03781089
- Testing
- Patiromer Oral Powder Product
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Glargine Versus NPH in Patients With Chronic Kidney Disease
Chronic kidney disease (CKD) is one of the most common microvascular complications of diabetes mellitus, and it is the leading cause of end stage renal disease on developed countries.
- Trial name
- NCT02451917
- Testing
- Glargine insulin, NPH insulin
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo General Hospital
Chronic Kidney Diseases, Type 2 Diabetes
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability.
- Trial name
- CANDY-CANE (NCT02608177)
- Testing
- Linagliptin, Glipizide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Gout
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
- Trial name
- EXCEL (NCT00175019)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,086 people
- Sponsor
- Takeda